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Background: A germline mutation of KEAP1 gene was reported as a novel genetic 
abnormality associated with familial multinodular goiter. That report was limited, and the 
pathogenic features were not well established.
patient findings: We report a 47-year-old Japanese woman who presented with hyper-
thyroidism and a large multinodular goiter. The family history was notable for a paternal 
history of goiter. Graves’ disease was diagnosed based on positive TRAb, but scintiscan 
imaging showed that the patient’s radioiodine uptake was restricted in the non-nodular 
areas, indicating largely cold nodules. A total thyroidectomy was performed. The resected 
thyroid tissue weighed 209 g, and subsequent pathological findings were benign. The 
patient had a germline heterozygous KEAP1 mutation, c. 1448 G > A, resulting in an 
amino acid substitution (p.R483H). A next-generation sequencing analysis covering all 
known genes associated with multinodular goiter showed no additional germline muta-
tion. The nuclear accumulation of NRF2, a protein associated with KEAP1, was shown 
at much higher rates in the patient’s nodules compared with nodules obtained from four 
unrelated patients with multinodular goiters.
Conclusion: A novel germline mutation (R483H) of KEAP1 gene was associated with 
the development of a non-toxic multinodular goiter.
Keywords: Keap1 germline mutation, multinodular goiter, familial goiter, NRF2 expression, Graves’ disease
INtRoDUCtIoN
The development of a multinodular goiter is associated with various factors such as genetic abnormali-
ties, iodine deficiency, and natural goitrogens. A germline mutation of Kelch-like ECH-associated 
protein 1 (KEAP1) gene was reported as a novel molecular cause of familial multinodular goiter (1). 
This mutation is a frameshift mutant (D294T, fs*23) in KEAP1, and the truncated KEAP1 protein 
is not generated (1). KEAP1 was originally identified as a protein associated with nuclear factor 
erythroid-2-related factor 2 (NRF2) (2) and also functions as a substrate adaptor protein for a Cul3-
dependent E3 ubiquitin ligase complex, with a subsequent degradation of NRF2 by the proteasome 
(3). Oxidative stress or electrophiles inactivate KEAP1 by the modification of cysteine residues in 
KEAP1, which results in the decline of ubiquitin activity and thereby the facilitation of the nuclear 
taBLe 1 | Genes and exons included in Goiter ampliseq panel.
Gene Chromosomes No. of exons Incomplete exons
NRAS chr1 4
TPO chr2 18 Exons 8 and 9
THRB chr3 8
IYD chr6 7
SLC26A4 chr7 21 Exon 17
TG chr8 48
RET chr10 21 Exon 1
HRAS chr11 5
KRAS chr12 5
TSHR chr14 12
DICER1 chr14 27
DUOX2 chr15 34 Exons 5, 6, and 7
DUOXA2 chr15 6
SLC5A5 chr19 15 Exons 1, 4, 7, and 12
KEAP1 chr19 5
FIGURe 1 | Imaging study. CT scan showing multinodular enlargement of the thyroid gland (a). The corresponding region of radioiodine uptake represents cold 
nodules in this SPECT/CT fusion image (B).
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accumulation of NRF2 shifting from the cytoplasmic localization. 
As a key molecule for the response of oxidative stresses or electro-
philes, NRF2 activates the transcription of various cytoprotective 
genes that enhance cell proliferation (4).
In another aspect, KEAP1 mutations are sufficient to lead to a 
constitutive activation of NRF2 by disrupting the KEAP1–NRF2 
interaction. Somatic mutations in KEAP1 gene in cancer tissues 
and cancer-derived cell lines of different origins affect the repres-
sive activity of KEAP1, stimulate the nuclear accumulation of 
NRF2, and provide advantages for cell growth (4). However, 
a germline mutation in KEAP1 has not yet been reported in 
familial cancer cases; it was detected only in a family with mul-
tinodular goiter (1). In this report, we describe a hyperthyroid 
patient who had a large multinodular goiter. She had a family 
history of goiter and carried a germline mutation (R483H) in 
KEAP1 gene.
patIeNt
the patient and Her Family
A 47-year-old Japanese woman consulted our hospital for the 
examination of a large goiter. Neck computed tomography (CT) 
showed multinodular lesions in both lobes (Figure  1A), and 
there were no abnormal findings on chest CT. She presented 
with subclinical hyperthyroidism (FT4: 1.53 ng/dl, FT3: 3.47 pg/
ml, and TSH: 0.011 μIU/ml) and high levels of thyroglobulin 
(Tg; 742.5  ng/ml). Anti-thyroid peroxidase (TPO) antibod-
ies and anti-Tg antibodies were negative. Scintiscan imaging 
showed radioiodine uptake in the non-nodular area of the 
thyroid isthmus, but absence in the nodular lesions of both lobes 
(Figure 1B). The radioiodine uptake at 3 h was 8.3% within the 
normal range.
Specimens obtained from the thyroid nodules by fine-needle 
aspiration were categorized as benign based on the Bethesda 
system. Seven months later, the diagnosis of Graves’ disease was 
made based on the patient’s overt hyperthyroidism (FT4: 3.17 ng/
dl, FT3: 12.27  pg/ml, and TSH: <0.003  μIU/ml) and positive 
TRAb (7.9 IU/l). She entered remission 25 months after starting 
methimazole therapy, but the Graves’ hyperthyroidism relapsed 
thereafter. She underwent a total thyroidectomy that included the 
persistently large goiter, and the weight of the resected thyroid 
tissue was 209 g.
MateRIaLs aND MetHoDs
screening of Goiter-associated Gene 
Variants by Next-Generation sequencing
We performed a next-generation sequencing (NGS) analysis 
targeted to most of the coding exons of goiter-associated genes 
(Goiter Ampliseq panel, Table 1), using custom primers designed 
by Ion Ampliseq Designer (Life Technologies, Carlsbad, CA, 
USA), according to the manufacturer’s instructions. Briefly, 
genomic DNA was isolated from whole blood samples with a 
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany), and 
a multiplex polymerase chain reaction (PCR) of a total of 429 
amplicons (Table 1) was performed, followed by the addition of 
Ion Xpress Barcode Adaptors, with the Ion Ampliseq Library Kit 
2.0 (Life Technologies).
After enrichment by clonal emulsion PCR on Ion Sphere 
particles (Ion PGM Template OT2 200 Kit), the barcoded librar-
ies were loaded on an Ion 318 chip, and massively paralleled 
FIGURe 2 | Histopathological features and immunohistochemical detection of NRF2 in the thyroid. A histopathological feature (a) of a left lobe shows 
non-nodular parenchyma (#) and a partially encapsulated follicular nodule (*). A greater nuclear accumulation of NRF2 was detected in a nodular lesion of the patient 
(C) than in a non-nodular parenchyma of the patient (B) and a nodular lesion in a control (D). The data shown are representative of two experiments with similar 
results. Original magnification; 40× (a), 400× (B–D).
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sequencing was carried out on an Ion Torrent PGM sequencer 
with the Ion PGM Sequencing 200 Kit version 2.
sequence Data analysis
We analyzed the raw signal data of NGS by using Torrent Suite 
software (ver. 5.0.4), including adaptor trimming, read alignment 
to human genome 19 reference, coverage analysis, and variant 
calling. To determine whether the detected sequence variants are 
known pathogenic mutations or novel variants, we carried out 
variant filtration as well as annotation by using Ion Reporter soft-
ware (ver. 5.0; Life Technologies). Sequence variant confirmation 
was performed by conventional Sanger methods with a BigDye 
Terminator Cycle Sequencing Kit (Applied Biosystems, Foster 
City, CA, USA). This study was approved by the Ethics Committee 
of Kuma Hospital, and informed consent was obtained from the 
patient and her family members for the use of their blood and 
tissue samples for research purposes.
Histopathological evaluation and 
Immunohistochemistry
After surgical resection, the thyroid tissues were routinely fixed in 
10% neutral buffered formalin, and specimens were embedded in 
paraffin. Serial sections (3-μm thick) were cut from each paraffin 
block. For the light-microscopic examination, the sections were 
stained with hematoxylin–eosin (HE). The immunostaining 
for human NRF2 (rabbit polyclonal, C-20, 1:50, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) was performed using the 
Leica Bondmax system (Leica Microsystems, Wetzlar, Germany) 
and a Bond refine kit (Leica Microsystems) according to the 
manufacturer’s instructions. Antigen retrieval was performed 
using Bond Epitope Retrieval Solution 1 (pH 6) at 100°C for 
60 min. Control specimens were obtained from four unrelated 
patients with large multinodular goiters (>100 g) and negative 
anti-TPO and anti-Tg antibodies.
ResULts
Histopathology and Family History
The subsequent histopathological findings of the thyroid 
specimens showed that both lobes of the thyroid was almost 
completely occupied by multinodular lesions that were partially 
encapsulated by fibrous tissue and concomitantly degenerative 
cystic structures without lymphoid infiltration in the stroma. The 
nodules were composed of various-sized thyroid follicles and 
showed largely high cellularity due to a microfollicular pattern 
with columnar epithelial cells (Figure  2A). The internodular 
thyroid parenchyma showed almost normal morphology, and 
malignant findings were not identified.
The patient’s father had presented with a marked goiter but 
had died earlier due to head injury. She had a family history 
of large goiter in two paternal aunts who were unavailable to 
undergo genetic testing (Figure 3). The patient’s mother, son, and 
daughter were euthyroid and had no goiter or nodular lesion on 
ultrasonography of the neck.
Identification of Keap1 Gene Mutation
To identify any known germline mutation of goiter-associated 
genes, we first performed a targeted-NGS analysis of the patient’s 
FIGURe 4 | KEAP1 gene analysis. Sequencing analysis of KEAP1 in genomic DNA extracted from the proband’s peripheral blood leukocytes. A heterozygous 
guanine-to-adenine transition at position 1448 (indicated by arrows) was identified in the proband (a), and a wild-type sequence was shown in her mother (B).
FIGURe 3 | pedigree of the investigated family. Individuals affected with 
goiter are indicated by filled symbols. The arrow shows the proband in this 
study. The bars above each symbol indicate individuals who underwent a 
sequencing analysis for KEAP1 gene.
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genomic DNA from peripheral blood leukocytes with the Goiter 
Ampliseq panel (Table 1). The proband had 27 exonic variants 
identified in the Single Nucleotide Polymorphism database 
(dbSNP) and one heterozygous exonic variant in KEAP1 (c.1448 
G > A, p.R483H) not registered in the dbSNP. According to the 
NCBI’s ClinVar database,1 the detected 27 variants in dbSNP, 
including 16 missense polymorphisms, have not been reported 
as pathogenic mutations.
Although several exons of target genes were not completely 
sequenced with the Goiter Ampliseq panel (Table  1), conven-
tional Sanger sequencing indicated no pathogenic polymorphism 
in those exons. Our subsequent analysis by Sanger methods 
1 http://www.ncbi.nlm.nih.gov/clinvar/ 
validated the heterozygous mutation of c.1448 G > A in KEAP1 
in the patient (Figure 4A).
Our sequence analysis of genomic DNA from the proband’s 
16-year-old son showed an identical heterozygous guanine-to-
adenine transition at position 1448; however, it was absent in the 
proband’s daughter and mother (Figure 4B). The R483H variant 
was evaluated as “disease causing or deleterious” by Mutant 
Taster,2 PolyPhen2,3 PROVEAN,4 and PANTHER.5 This variant 
was not described previously in other individuals by the 1000 
Genome Project6 or the Exome Aggregation Consortium.7
NFR2 expression in the thyroid
In this patient, NRF2 positive staining in the nuclei was detected 
in >30% of the cells in nodular lesions (Figure 2C) but in <10% 
of the cells in the non-nodular parenchyma (Figure 2B). In all 
four control specimens, a nuclear accumulation of NRF2 was 
detected in <10% of the cells in both the nodular lesions and the 
non-nodular parenchyma (Figure 2D and data not shown).
DIsCUssIoN
We report a hyperthyroid patient harboring a novel germline 
mutation (R483H) in KEAP1 gene who presented with a large 
2 http://www.mutationtaster.org/ 
3 http://genetics.bwh.harvard.edu/pph2/index.shtml 
4 http://provean.jcvi.org/seq_submit.php 
5 http://www.pantherdb.org/tools/csnpScoreForm.jsp 
6 http://www.1000genomes.org/ 
7 http://exac.broadinstitute.org/ 
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multinodular goiter and Graves’ disease. The R483H mutation in 
KEAP1 is not present as a polymorphism in several databases. 
The amino acid residue of R483 is strongly conserved in mam-
mals and is essential for the molecular interaction with NRF2 
(5). The binding capability of a mutant KEAP1 with NRF2 can 
be estimated by the cellular localization of NRF2, which presents 
with nuclear accumulation by a dissociation of KEAP1 binding 
in the cytoplasm (2). Indeed, the nuclear accumulation of NRF2 
was shown at much higher rates in the nodules in this patient 
than in the nodules obtained from four unrelated patients with 
multinodular goiter (Figures 2B–D).
The direct target genes of NRF2 include the synthesis and 
conjugation of glutathione, antioxidant substance, and metabolic 
enzymes, which can protect from oxidative stresses that may 
occur during thyroid hormone synthesis and confer multiple 
advantages of cell proliferation (4). In Keap1–null mice, these 
target genes of NRF2 are constitutively upregulated, whereas its 
upregulation is reversed in Keap1/Nrf2 double-deficient mice (6), 
suggesting that impaired KEAP1 function leads to the constitu-
tive stabilization of NRF2. Although a previous report showed 
that the lower expression of wild-type KEAP1 by a frameshift 
mutation is a possible pathogenesis of multinodular goiter (1), 
our present analysis is the first to demonstrate that a single amino 
acid substitution in KEAP1 could lead to the development of a 
multinodular goiter.
Somatic mutations in KEAP1 were reported to occur in 60% 
of lung cancers (7). The R483H somatic mutation in KEAP1 has 
been reported in lung cancer tissue with elevated levels of NRF2 
expression (8). In addition, oncogenes, such as KRAS, BRAF, 
and C-MYC, can stimulate NRF2 transcription and activation 
in cancer cells (9). Concomitant abnormalities of oncogenes 
and KEAP1 gene may affect tumorigenesis and accelerate the 
growth of cancer cells. On the other hand, the presence of 
the R483H germline mutation in KEAP1 did not result in any 
nuclear accumulation of NRF2 in the non-nodular parenchyma 
of our patient, and no thyroid nodule was detected by ultra-
sonography in her 16-year-old son, who has same KEAP1 
mutation as the patient. Our NGS analysis, which covered all 
known genes associated with multinodular goiter including a 
battery of thyroid hormone synthesis genes, TSH receptor, and 
DICER1 showed no additional genetic abnormalities in the 
patient. These findings suggest that the nodular formation in 
multinodular goiter may be influenced by microenvironmental 
changes including loss of heterozygosity of KEAP1, because 
the thyroid gland is most susceptible to oxidative stress during 
hormone synthesis, which can lead to an additional somatic 
mutation at a high frequency.
It is unknown whether this KEAP1 mutation may affect any 
aspect of Graves’ disease, but the thyroid gland of our patient was 
almost completely occupied by cold nodules without lymphoid 
infiltration in the stroma, suggesting that her large goiter was 
due not to her Graves’ disease but rather to the cold nodules. 
Collectively, our findings indicated that a novel germline muta-
tion (R483H) of KEAP1 gene is associated with the development 
of a non-toxic multinodular goiter as one pathogenesis.
aUtHoR CoNtRIBUtIoNs
Study design: EN. Experiment: EN, AH, TK, and NT. Interpretation 
of data: EN, AH, TK, NT, MH, SF, MI, TY, MN, HN, NA, and AM. 
Drafting the work or revising it critically: EN, AH, TK, NT, MH, 
SF, MI, TY, MN, HN, NA, and AM. Final approval of the version 
to be published: EN, AH, TK, NT, MH, SF, MI, TY, MN, HN, NA, 
and AM. Agreement to be accountable for all aspects of the work: 
EN, AH, TK, NT, MH, SF, MI, TY, MN, HN, NA, and AM.
aCKNoWLeDGMeNts
This work was supported by Medical Research Fund of Hyogo 
Medical Association (MRF-H-7-15).
ReFeReNCes
1. Teshiba R, Tajiri T, Sumitomo K, Masumoto K, Taguchi T, Yamamoto K. 
Identification of a KEAP1 germline mutation in a family with multinodular 
goitre. PLoS One (2013) 8:e65141. doi:10.1371/journal.pone.0065141 
2. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, et  al. Keap1 
represses nuclear activation of antioxidant responsive elements by Nrf2 through 
binding to the amino-terminal Neh2 domain. Genes Dev (1999) 13:76–86. 
doi:10.1101/gad.13.1.76 
3. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, et al. Oxidative 
stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate 
proteasomal degradation of Nrf2. Mol Cell Biol (2004) 24:7130–9. doi:10.1128/
MCB.24.16.7130-7139.2004 
4. Suzuki T, Motohashi H, Yamamoto M. Toward clinical application of the 
Keap1-Nrf2 pathway. Trends Pharmacol Sci (2013) 34:340–6. doi:10.1016/ 
j.tips.2013.04.005 
5. Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, Yamamoto M. Keap1 
recruits Neh2 through binding to ETGE and DLG motifs: characterization of 
the two-site molecular recognition model. Mol Cell Biol (2006) 26:2887–900. 
doi:10.1128/MCB.26.8.2887-2900.2006 
6. Wakabayashi N, Itoh K, Wakabayashi J, Motohashi H, Noda S, Takahashi S, 
et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 
activation. Nat Genet (2003) 35:238–45. doi:10.1038/ng1248 
7. Li QK, Singh A, Biswal S, Askin F, Gabrielson E. KEAP1 gene mutations and 
NRF2 activation are common in pulmonary papillary adenocarcinoma. J Hum 
Genet (2011) 56:230–4. doi:10.1038/jhg.2010.172 
8. Takahashi T, Sonobe M, Menju T, Nakayama E, Mino N, Iwakiri S, 
et  al. Mutations in Keap1 are a potential prognostic factor in resected 
non-small cell lung cancer. J Surg Oncol (2010) 101:500–6. doi:10.1002/ 
jso.21520 
9. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. 
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tum-
origenesis. Nature (2011) 475:106–9. doi:10.1038/nature10189 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Nishihara, Hishinuma, Kogai, Takada, Hirokawa, Fukata, Ito, 
Yabuta, Nishikawa, Nakamura, Amino and Miyauchi. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
